Covid-19 roundup: Novartis' Vas Narasimhan sees drugs as 'bridge' to vaccines; Moderna spotlights elderly responses in NEJM
Novartis may be staying out of the vaccine pack, but the Swiss pharma giant insists that its drugs will still have a crucial role to play.
CEO Vas Narasimhan made his case again in a new interview with Bloomberg, arguing that even if the leading vaccines are shown to be highly effective, they probably won’t be available in large numbers until the end of next year. Even then, it likely won’t protect everyone equally well.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 94,000+ biopharma pros reading Endpoints daily — and it's free.